Short Summary
Nexus Pharmaceuticals has filed a PGR petition challenging all 30 claims of Exela Pharma Sciences' L‑cysteine parenteral nutrition patent, asserting lack of enablement, insufficient written description, and, alternatively, obviousness over the Sandoz label.
Detailed Summary
In a petition for post‑grant review of U.S. Patent No. 11,642,370, Nexus Pharmaceuticals contends that the patent’s claims covering stable L‑cysteine solutions for total parenteral nutrition are not enabled because the specification provides only narrow examples and does not teach how to achieve the broad ranges of aluminum, oxygen, pH, and concentration without undue experimentation. The petition also argues that the specification lacks a sufficient written description to support the full claim scope. As an alternative, Nexus asserts obviousness over the publicly available Sandoz label and related prior art, should the enablement arguments fail. The petition seeks cancellation of all 30 claims and references extensive district‑court findings and prior PTAB proceedings involving related patents.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Nexus Pharmaceuticals LLC vs Exela Pharma Sciences, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Google LLCvsSecure Communication Technologies, LLC
Google petitions the PTAB to invalidate claims of a mobile‑commerce patent, asserting anticipation by Perttila and obviousness over Perttila combined with Swartz. The petition seeks institution of review under §§102 and 103.
Catalyst OrthoScience Inc.vsShoulder Innovations, Inc.
Catalyst OrthoScience seeks a PTAB post‑grant review of Shoulder Innovations' reverse shoulder implant patent, arguing obviousness over multiple prior‑art references and indefiniteness of the term “central channel.” The petition also asserts that discretionary denial is unwarranted.
Merck Sharp & Dohme LLCvsHalozyme, Inc. et al.
Merck has filed a PGR petition challenging Halozyme’s U.S. Patent 12,110,520 covering engineered PH20 hyaluronidase proteins. The petition asserts lack of written description, lack of enablement, and obviousness over prior art. The Board has not yet ruled.
BOE Technology Group Co., Ltd.vsSamsung Display Co., Ltd.
BOE Technology and Samsung Display have settled all disputes in IPR2025-01499 concerning U.S. Patent 9,299,730. They jointly filed a motion to terminate the inter partes review under 35 U.S.C. § 317, citing that the Board has not decided the merits and that settlement serves public policy interests.
Apple Inc.vsVampire Labs, LLC
Apple has filed an IPR petition challenging all 14 claims of Vampire Labs' battery‑charging patent, arguing that the claims are obvious over prior art (Stephens, Horowitz, and Toya) and that discretionary denial is unwarranted. The petition seeks institution of the proceeding and cancellation of the claims.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.